APAC Long-Acting HIV Treatment Market Industry Trends and Forecast to 2034: Segmented by (Use, Drug, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
APAC · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$452.2 MnPlaceholder estimate
Estimate 2025$549.9 Mn19.1% of the global market
Projected 2034$3.20 Bn 481.3%Adds $2.65 Bn over 9 forecast years
CAGR 2025–203421.6%Faster than 89% of 180 Pharmaceuticals markets here
Key players4
APAC is 19.09% of the global market.
Among regions, the largest is North America at $1.48 Bn.
Fastest growing: APAC (this report) at 21.6% a year.
APAC ranks 2nd of 6 by size among regions.
Market size projection
APAC
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
Value added each year
$2.65 Bn total, 2026–2034
Year-by-year market size, 2024–2034
Long-Acting HIV Treatment Market market size by year, APAC
Year
Market size
Change that year
Since 2025
2024 (estimate)
$452.2 Mn
—
—
2025 (base)
$549.9 Mn
+$97.7 Mn
—
2026 (forecast)
$668.7 Mn
+$118.8 Mn
+21.6%
2027 (forecast)
$813.1 Mn
+$144.4 Mn
+47.9%
2028 (forecast)
$988.8 Mn
+$175.6 Mn
+79.8%
2029 (forecast)
$1.20 Bn
+$213.6 Mn
+118.6%
2030 (forecast)
$1.46 Bn
+$259.7 Mn
+165.9%
2031 (forecast)
$1.78 Bn
+$315.8 Mn
+223.3%
2032 (forecast)
$2.16 Bn
+$384.0 Mn
+293.1%
2033 (forecast)
$2.63 Bn
+$467.0 Mn
+378%
2034 (forecast)
$3.20 Bn
+$567.8 Mn
+481.3%
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
ViiV Healthcare, Gilead Sciences, Inc., Johnson & Johnson, Merck & Co., Inc. (see all)
Active clinical trials
9 in Asia PacificSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The APAC Long-Acting HIV Treatment Market Analysis Executive Summary
Long-acting HIV treatments and prevention are given as injections every few months instead of daily pills.
Key segments of the long-Acting HIV Treatment market include use (Treatment and Pre-Exposure Prophylaxis (PrEP)) and drug (Cabotegravir, Lenacapavir and Rilpivirine).
Asia Pacific Long-Acting HIV Treatment market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
APAC Long-Acting HIV Treatment Market Dynamics
Market Growth Drivers
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the long-Acting HIV Treatment market.
Opportunity
New vaccines, rapid tests and public-private funding for neglected diseases give the long-Acting HIV Treatment market room to grow, especially in Asia, Africa and Latin America.
Market Restraints
Low prices in poorer markets, weak returns for new antibiotics, vaccine hesitancy and cold-chain problems hold back the long-Acting HIV Treatment market.
Competitive Landscape for Long-Acting HIV Treatment Market in APAC
The long-Acting HIV Treatment market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Long-Acting HIV Treatment Market in APAC
Long-Acting HIV Treatment in APAC: rules, payment and research
In some of the countries we cover here, medicines are approved by TGA (Australia)[1], NMPA (China)[2], Drug Office (Hong Kong)[3], CDSCO (India)[4], PMDA (Japan)[5], NPRA (Malaysia)[6], Medsafe (New Zealand)[7], FDA Philippines (Philippines)[8], HSA (Singapore)[9] and Thai FDA (Thailand)[10]. How care is paid for in some of these countries: Medicare and the PBS (Australia)[11], basic medical insurance (China)[12], the Hospital Authority (Hong Kong)[13], Ayushman Bharat PM-JAY (India)[14], public health insurance (Japan)[15], subsidised public care (Malaysia)[16], Pharmac (New Zealand)[17], PhilHealth (Philippines)[18], MediShield Life (Singapore)[19] and the Universal Coverage Scheme (Thailand)[20]. ClinicalTrials.gov lists 9 studies on Long-Acting HIV Treatment that are recruiting, active or about to start in APAC.[21]
[21]ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in APAC. Retrieved 12 Nov 2026.
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for long-Acting HIV Treatment. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Use
4.2 By Drug
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 ViiV Healthcare
7.2 Gilead Sciences
7.3 Johnson & Johnson
7.4 Merck & Co.
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The long-Acting HIV Treatment market can be segmented based on various criteria, including use, drug and end user. Here's a breakdown of the market segmentation
What doctors and scientists are doing in Long-Acting HIV Treatment right now, from free public sources.
Clinical trials
9 active trials in China, India, Japan, Australia, Hong Kong, Philippines, Singapore, Thailand, Malaysia, New Zealand, Bangladesh, Afghanistan, Indonesia, Myanmar, Nepal and Pakistan
Recruiting, about to start, or running now. Counted across the 16 countries we report on in APAC.
Sources:PubMed (US National Library of Medicine),
ClinicalTrials.gov,
WHO Global Health Observatory.
Fetched 15 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
How big is the Long-Acting HIV Treatment market in Asia Pacific?
Placeholder estimate: about $549.9 Mn in 2025, rising to about $3.20 Bn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Long-Acting HIV Treatment market in Asia Pacific growing?
Placeholder estimate: about 21.6% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Long-Acting HIV Treatment market report cover?
The report splits the market by use (Treatment, Pre-Exposure Prophylaxis (PrEP)), drug (Cabotegravir, Lenacapavir, Rilpivirine) and end user (Hospitals, Specialty Clinics, Retail Pharmacies, Online Pharmacies).
Who are the key players in the Long-Acting HIV Treatment market?
Key players include ViiV Healthcare, Gilead Sciences, Inc., Johnson & Johnson and Merck & Co., Inc..
What is driving the Long-Acting HIV Treatment market?
Rising antimicrobial resistance, outbreaks of new and returning diseases, climate change spreading infections and strong global funding for prevention are driving the long-Acting HIV Treatment market.
How many clinical trials on Long-Acting HIV Treatment are running in Asia Pacific?
9 studies are recruiting, active or about to start in Asia Pacific, counted across the 16 countries we report on there, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Asia Pacific. Retrieved 12 Nov 2026.
How much research is published on Long-Acting HIV Treatment?
PubMed lists 17 papers on Long-Acting HIV Treatment added since January 2021, worldwide. Source: PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.